This section exemplifies studies around tumor resistance in a CRISPR-induced mouse model of anaplastic lymphoma kinase (Alk) positive non-small cell lung cancer (NSCLC), for which adenoviral particles expressing the CRE recombinase and the CRISPR/Cas9 system were administered intra-tracheally. This evidence concerns the gene ALK and non-small cell lung carcinoma.